CVRx COO awarded 16,600 shares and 74,900 options; $7.51 strike
Rhea-AI Filing Summary
Brent Binkowski, Chief Operating Officer of CVRx (CVRX), acquired equity awards on 08/11/2025 that increase his direct stake in the company. He received 16,600 restricted stock units that vest 25% on each anniversary of the grant date, and was granted stock options for 74,900 shares with an exercise price of $7.51. The options vest 25% after one year and then 1/48th per month thereafter and have an expiration date listed as 08/10/2035. Following these transactions, the reporting person directly beneficially owns 16,600 shares and holds options for 74,900 shares.
Positive
- Acquisition of 16,600 restricted stock units, increasing direct ownership and aligning the COO with shareholder value
- Grant of 74,900 stock options with a standard multi-year vesting schedule, supporting executive retention and long-term alignment
Negative
- Potential dilution of 74,900 shares from the option grant (combined potential interest of 91,500 shares), though percentage impact is not disclosed
- Vesting delays mean the options and some RSUs are not immediately exercisable, limiting near-term voting or liquidity impact
Insights
TL;DR: Routine executive compensation grants that align management with shareholders through multi-year vesting.
The reported awards to the COO are structured as time-based equity compensation: restricted stock units that vest 25% per year and options that vest 25% after one year then monthly thereafter. This structure is consistent with retention and alignment practices, linking pay to continued service. The direct ownership after the grants is 16,600 shares and 74,900 options, both held directly. Without outstanding share counts, the materiality to existing shareholders cannot be quantified, but the grant design is typical for executive retention.
TL;DR: Insider acquired 16,600 RSUs and 74,900 options at $7.51; potential dilution equals 91,500 shares but impact needs total share count.
The transaction increases the reporting person's economic exposure by 16,600 shares delivered as restricted stock units and by the right to purchase 74,900 shares at an exercise price of $7.51. Combined, that represents 91,500 shares of current or potential direct interest. The options expire on 08/10/2035 and vest over time, limiting immediate convertibility. Assessing investor impact requires the company's outstanding share count and any previously outstanding in-the-money awards; those figures are not provided in this filing.